Realbotix Sets Clear Path Forward with Financial Reporting Schedule

Realbotix files delayed 2025 financials, sets timeline for Q1 results and key investor call to discuss strategic merger with Onconetix and regulatory compliance.

Realbotix has provided specific dates for releasing its outstanding financial statements, marking a significant move toward regaining full regulatory compliance. This clarity comes after reporting delays triggered by a leadership transition within the finance department. The newly established timeline for audited annual figures and subsequent investor communication is particularly crucial for the market, given the company's pending merger with Onconetix.

Regulatory Scrutiny and Management Trading Ban

The delays in financial reporting resulted in a Management Cease Trade Order being imposed by regulators at the end of January 2026. This action was directly linked to the health-related departure of the outgoing Chief Financial Officer and the ensuing transition period. The order prohibited members of the executive team from trading the company's securities, though it did not affect regular market trading for shareholders.

With the audited financial statements for fiscal year 2025 now filed as of Friday, March 6, the company will follow with the release of its unaudited interim reports for Q1 on Monday, March 9. CEO Andrew Kiguel has emphasized that no material information was withheld during this period and that all previous market communications remain valid.

Strategic Pivot: The Onconetix Acquisition

These filings serve as a direct precursor to an investor conference call scheduled for Tuesday, March 10. Management intends to use this forum not only to discuss the financial results but also to provide details on a strategic realignment. The focal point is the previously announced acquisition of Realbotix LLC by Onconetix, a deal unveiled in February.

Structured as a share exchange, the transaction is expected to leave Realbotix's parent company holding between 75 and 90 percent of the combined entity post-merger. Market participants are anticipating updates that will shed light on the integration roadmap and the future strategic direction for the robotics division.

The company's shares have faced pressure amid recent uncertainties, currently trading at €0.17, a level just above its 52-week low. Technically, the stock appears deeply oversold, reflected in a Relative Strength Index (RSI) reading of 19.2.

During the Tuesday webcast, executives are expected to provide a detailed commentary on both the financials and the strategic integration with Onconetix. Until the transaction's anticipated close in the second half of 2026, the primary drivers for the share price are likely to be measurable progress in the merger process and the operational performance of the robotics business unit.